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This contribution explores in a new statistical perspective the antibody responses to
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 141 coronavirus
disease 2019 (COVID-19) patients exhibiting a broad range of clinical manifestations.
This cohort accurately reflects the characteristics of the first wave of the SARS-CoV-2
pandemic in Italy. We determined the IgM, IgA, and IgG levels towards SARS-CoV-2 S1,
S2, and NP antigens, evaluating their neutralizing activity and relationship with clinical
signatures. Moreover, we longitudinally followed 72 patients up to 9 months
postsymptoms onset to study the persistence of the levels of antibodies. Our results
showed that the majority of COVID-19 patients developed an early virus-specific antibody
response. The magnitude and the neutralizing properties of the response were
heterogeneous regardless of the severity of the disease. Antibody levels dropped over
time, even though spike reactive IgG and IgA were still detectable up to 9 months. Early
baseline antibody levels were key drivers of the subsequent antibody production and the
long-lasting protection against SARS-CoV-2. Importantly, we identified anti-S1 IgA as a
good surrogate marker to predict the clinical course of COVID-19. Characterizing the
antibody response after SARS-CoV-2 infection is relevant for the early clinical
management of patients as soon as they are diagnosed and for implementing the
current vaccination strategies.
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In December 2019, the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) was identified as the causative
agent of the coronavirus disease 2019 (COVID-19). Nowadays,
the pandemic remains a dramatic global challenge due to the
unpredictable disease outcome and the rapid emergence of
genetic variants. It became clear very quickly that COVID-19
was characterized by highly variable clinical manifestations
ranging from asymptomatic to mild and moderate, while
progressing to respiratory and multiorgan failure in certain
patients, even leading to death (1).
IgM, IgA, and IgG targeting the viral spike (S) and
nucleoprotein (NP) are sequentially or concomitantly
generated promptly after infection (2, 3). Antibody production
reduces the risk of severe disease and neutralizing antibodies
(nAbs) represent important correlates of protection against viral
infections (4). Several studies examined the magnitude, the
dynamic, the persistence, and the functions of SARS-CoV-2-
specific antibodies; however, the evidences are not concordant
across the studies (5–7).
The antiviral response towards SARS-CoV and MERS-CoV
remained detectable for an average of 2 years (8) and less than 1
year (9) after primary infection, respectively. The persistence of
SARS-CoV-2-protective antibodies is still under investigation.
Given the heterogeneity of COVID-19, identifying
biomarkers, within a multivariate perspective, plays a crucial
role in early diagnosis, monitoring, and management of patients,
complementing the clinical assessment of the disease. Current
available biomarkers (10) attempted at identifying subjects at
high risk to develop the disease, and they allowed confirming the
diagnosis, assessing the severity, discriminating the requirement
of hospital care, driving the administration, and the response to
therapy. However, their performance in terms of clinical utility
remains to be evaluated and the discovery of novel biomarkers is
a clinical unmet need.
In the recent literature, data-driven approaches have been
proved as very sensitive in identifying risk factor effects for
clinical outcomes in COVID-19 case series data collected with no
design in emergency conditions (11, 12). We here apply
machine-learning algorithms to profile the antibody landscape
of a heterogeneous SARS-CoV-2-infected cohort of patients,
thus identifying specific signatures allowing to drive the early
diagnosis and predict the clinical course of COVID-19.
We also assessed the longevity of the naturally induced
antibodies against the wild-type virus and their capability to
cross-neutralize the current circulating variants of concerns.MATERIALS AND METHODS
Patient Selection and Data Collection
Plasma samples from 141 SARS-CoV-2-infected subjects
between February and May 2020 admitted to the Emergency
or Clinical departments of the Istituto di Ricovero e Cura a
Carattere Scientifico (IRCCS) San Raffaele Hospital or healthcareFrontiers in Immunology | www.frontiersin.org 2workers from care-home residents were included in this study.
The inclusion criterion for this clinical-biological case series
study is provided in the SI Appendix.
Cell Line
Human embryonic kidney 293 cells (HEK 293T/17 cells) were
acquired from Programme EVA Centre for AIDS Reagents,
National Institute for Biological Standards and Control (NIBSC,
UK), cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 4.5 mg/ml glucose, 2 mM L-glutamine (Lonza,
Basel, Switzerland), 100 units/ml penicillin-streptomycin (Lonza)
and 10% of FBS (Euroclone, Milan, Italy). The cells were incubated
at 37°C, 5% CO2 in humidified atmosphere.
Production and Titration of SARS-CoV-2
Lentiviral-Pseudotyped Particles
SARS-CoV-2-pseudotyped particles were produced and titrated
as previously described (13) and briefly detailed in the
SI Appendix.
Neutralization assays were performed by incubating 106 RLU
of pseudotyped viruses with endpoint twofold serial dilutions of
heat-inactivated plasma samples at 37°C 5% CO2 for 1 h before
addition of 104 HEK 293T/17-ACE2/TMPRSS2 cells per well.
After 72 h at 37°C, the cells were lysed in Luciferase Assay
(Promega, Madison, WI, USA) and luciferase activity was
measured using a Victor luminometer. Neutralization titers
were expressed as IC50 values, defined as the concentration of
plasma required to achieve half maximal neutralization.
Purification of IgG and IgA
HiTrap Protein G HP 1 ml column (GE Healthcare, Boston, MA,
USA) and Peptide M-Agarose 2 ml column (InvivoGen Europe,
Toulouse, France) were used to purify IgG and IgA, respectively,
from 300 µl of plasma according to the manufacturing
instructions and using an automatic HPLC system (Biologic
DuoFlow, Bio-Rad Laboratories, Hercules, CA, USA).
Detection of SARS-CoV-2-Specific
Antibodies
IgA, IgG, and IgM specific for the S1 and S2 subunits were
detected in plasma samples as previously described in an in-
house ELISA (13). Briefly, recombinant S1 or S2 protein
(Abeomics, San Diego, CA, USA) was plated at 0.1 µg/well on
Maxisorp 96-well plates (Thermo Scientific, Waltham, MA,
USA) and incubated overnight at 4°C in 50 mM carbonate/
bicarbonate buffer at pH 9.5. After blocking for 1 h at 37°C
with PBS containing 10% BSA and 0.05% Tween 20, duplicate of
1:100 diluted plasma samples were plated and incubated for 1 h
at 37°C. When optical density (OD) values were higher than
2.0, the samples were further diluted and retested. Plasma
samples from 40 healthy donors collected before COVID-19
pandemic were used as negative controls. The plates were
then treated for 30 min at 37°C with 1:6,000 horseradish
peroxidase (HRP)-conjugated goat antihuman IgA, antihuman
IgG, or antihuman IgM (Southern Biotech, Birmingham, AL,
USA). Plates were developed using TMB 2C (KPL-SeraCare,November 2021 | Volume 12 | Article 772239
Siracusano et al. Antibody Response Patterns in COVID-19Milford, MA, USA), and the reaction was stopped with
10% sulfuric acid after 5 min. The OD values were read at
wavelengths of 450 and 620 nm using a PowerWave ELISA
reader (BioTek, Winooski, VT, USA). The cutoff value was
determined by calculating the mean OD + 3SD obtained with
healthy individuals.
IgG, IgA, and IgM to the NP were measured through SARS-
CoV-2 (COVID-19) ELISA Kits (Novatec, Baltimore, MD, USA)
according to the manufacturer’s instruction.
An initial screening for NP reactivity was performed to
evaluate positive candidate control samples for S1- and S2-
binding assays. One high- and one mid-reactive samples were
chosen as shown in Supplementary Table S5.
Cutoff values were arbitrarily established to correspond to
10 Arbitrary Units (AU) for both the in-house ELISA and
Novatec ELISA kits, and the specificity for all of the assays
ranged from 98.26% to 100%. The AU were calculated with the
formula: [mean OD (sample) × 10 AU (cutoff)]/mean
OD (cutoff).
The WHO International Standard (WHO IS, National
Institute for Biological Standards and Control, NIBSC, UK,
cod. 20/136) and the WHO Reference Panel (WHO RP,
NIBSC, cod. 20/268) for anti-SARS-CoV-2 antibody were
tested at 1:100 dilution in the in-house ELISA for S1 and S2
and the Novatec kit for NP as described above, to check the
concordance with our results (see Supplementary Table S5A).
The AU values obtained were then transformed in International
Units per milliliter (IU/ml) relative to WHO IS 20/136 using the
formula [AU (sample) × 1,000 (IU/ml)]/AU (WHO IS) (see
Supplementary Table S5B), and the conversion factors
calculated were the following: 58.2 for anti-S2 IgG, 76.5 for
anti-S2 IgA, 47.5 for anti-S1 IgG, 80.8 for anti-S1 IgA, 19.9 for
anti-NP IgG, and 39.4 for anti-NP IgA. The AU for IgM were not
transformed in IU/ml since WHO IS showed no reactivity in the
S1-, S2-, NP-IgM-binding assays.
Statistical Analysis
Median, interquartile range, minimum, and maximum values
have been used to summarize quantitative variables; frequency
distributions have been reported for categorical variables.
Spearman’s correlation coefficient has been used to examine
the relationship among quantitative variables.
Friedman test followed by Dunn’s multiple comparison tests
has been applied in the presence of repeated measures.
Tobit regression models have been estimated to model left
censored dependent variable.
Classification and Regression Trees (CART) analyses have
been performed to identify those variables that best discriminate
patients with different outcomes.
Linear mixed-effects models have been applied to examine the
dynamic of IC50 over time. A random effect was specified on
patients’ ID, thus leading to random intercept models. Backward
model selection procedures have been applied to obtain a smaller
set of relevant covariates, and post-hoc analyses have been
implemented to compare responses of different groups of
patients at a fixed time point. Detailed statistical methods are
reported in the SI Appendix.Frontiers in Immunology | www.frontiersin.org 3RESULTS
Patient’s Cohort
The cohort consisted of 141 COVID-19 individuals enrolled
between February and August 2020, including patients admitted
at San Raffaele Hospital in the COVID-19 clinical-biological case
series study (COVID-BioB) (ClinicalTrialsgov identifier
NCT04318366), and healthcare workers from care-home
residents in Lombardia, Piemonte, and Liguria regions
(Table 1). The median age was 56 years (range 24–94), and
males and females were balanced distributed (48.2% and 51.8%,
respectively). They experienced a wide range of clinical
manifestations, ranging from asymptomatic (13.5%), mild
(36.9%, WHO scores 1 and 2), moderate (34%, WHO scores 3
and 4), and severe (15.6%, WHO scores 5 and 6) symptoms.
Among them, 51.1% required hospital care and 11.3% passed
away. Plasma samples were collected at a median of 38.40 days
postsymptoms onset (PSO, range 1–252 days). When grouped by
time PSO, 54 subjects contributed to an early plasma sample
collected within 1 month (23 subjects at 0–7 days and 31 subjects
at 8–30 days), 21 subjects contributed a 31–60-day sample, 28
contributed a 2–4-month sample, and 19 contributed a 5–9-
month sample. Furthermore, 72 subjects provided longitudinal
plasma samples, of which 51 contributed a 2 time points and 21
contributed 3 time points.
SARS-CoV-2-Specific Antibody Responses
Span From Undetectable to Robust
We first investigated the development of binding IgA, IgM,
and IgG towards the NP and the S subunits, S1 and S2. The
limit of detection of the tests was set equal to 10 based on values
detected for 120 healthy individuals sampled in 2018, and
14 were randomly chosen as negative controls (referred as
prepandemic). The magnitude of the individual antibody
response was heterogeneous among the cohort stratified
according to the time of sampling PSO (Figure 1A). A fraction
of both asymptomatic and symptomatic patients (1.4%) did notNovember 2021 | Volume 12 | Article 772239)
TABLE 1 | Demographic and clinic characteristics of the cohort.
Total 141
Demographics
Age (median [IQR], range) 56.00 [47.00, 67.00] (24–94
Sex (% male) 48.2 (68/141)
Clinical characteristics
Asymptomatic (%) 13.5 (19/141)
WHO score
1 (%) 17 (24/141)
2 (%) 19.9 (28/141)
3 (%) 12.1 (17/141)
4 (%) 22 (31/141)
5 (%) 6.4 (9/141)
6 (%) 9.2 (13/141)
Days PSO to sample collection (median
[IQR], range)
38.40 [9.25, 107.62]
(1–252) [n = 122]
Hospitalized (%) 51.1 (72/141)
Days hospitalization (median [IQR], range) 18.5 [9.75, 35.75]
ICU (%) 10.6 (15/141)
Deceased (%) 11.3 (16/141)
Siracusano et al. Antibody Response Patterns in COVID-19A
B C
D
FIGURE 1 | SARS-CoV-2 antibody levels (A) and neutralizing antibody titers (IC50) (B) in prepandemic (n = 14), asymptomatic (n = 19), and symptomatic subjects
(n = 122). The latter were grouped based on days PSO and color coded according to the severity of the disease: green (mild), yellow (moderate), and red (severe).
(C) Spearman’s correlations between IC50 and SARS-CoV-2 antibodies in the symptomatic subjects with onset of symptoms of less or equal to 7 days (n = 23) and
between 8 and 30 days (n = 31). (D) IC50 of IgA- and IgG-purified fractions and IgA/IgG-depleted fractions from five randomly selected patients. The dashed lines
represent the cutoff of the ELISA tests (10 AU) or the lowest dilution (1:40) of the neutralization assay.Frontiers in Immunology | www.frontiersin.org November 2021 | Volume 12 | Article 7722394
Siracusano et al. Antibody Response Patterns in COVID-19develop any antibody response. The severity of the disease did
not affect antibody development, as suggested by comparable
levels between asymptomatic infections and subjects with
mild or more severe symptoms. Asymptomatic individuals
developed lower detectable levels of anti-NP antibodies
compared with symptomatic within 9 months PSO; 73.7% of
asymptomatic subjects elicited S1 IgG (median 18.11) and 78.9%
developed S2 IgG (median 12.51). The magnitude of the S1- and
S2-specific IgG response was comparable with that found in
symptomatic subjects. S1-, S2-, and NP-specific IgM in
asymptomatic individuals were undetectable at the time of
sampling from the positive swab (range 40–143 days from the
positive swab). The proportion of asymptomatic individuals with
detectable levels of anti-S1 IgA (63.2%) was higher than those
reporting symptoms and collected between 0 and 7 days PSO
(56.5%), and their levels were comparable (median 11.48 and
12.68, respectively).
All the three Ig isotypes were developed within 0–7 days PSO,
as previously reported (4, 14). Anti-S1 IgA, IgG, and IgM were
detected in 56.5% (median 12.68), 47.8% (median equal to 10),
and 52.2% (median 12.17) of patients, respectively. Anti-S2 IgA,
IgG, and IgM were developed in 34.8%, (median equal to 10),
60.9% (median 12.57), and 31.8% (median equal to 10) of
patients, respectively. IgA and IgG towards NP were the most
representative isotypes developed at this time point
(Supplementary Table S1), detected in 56.5% (median 14.78)
and 60.9% (median 21.98) of patients, respectively, whereas only
30.8% developed NP-IgM (median equal to 10).
Between 8 and 30 days PSO, 74.2% of patients developed
higher anti-NP IgA levels than those sampled at 0–7 days PSO
(median 32.63). NP-IgM were higher compared with the
previous time point as well (median 11.63) in the 50% patients.
Differently from antibodies specific for NP, the percentage
of patients developing anti-S1 isotypes was comparable with
that analyzed within 7 days PSO, even their levels were
higher [54.8% for IgA (median 15.67) and IgG (median 12.89),
64.5% for IgM (median 12.34)]. Similar proportions were
observed for S2-IgA [38.7% (median equal to 10)] and S2-IgG
[67.7% (median 13.68)], whereas 23.3% developed IgM
(median equal to 10). Of note, patients enrolled during this
time point mainly experienced moderate (61.3%) and severe
(35.5%) symptoms.
Between 31 and 60 days PSO, both the percentage of patients
with IgA and IgG towards S1 and S2 and their respective levels
increased (71.4% (median 19.28) and 95.2% (median 18.38) for
S1 and 47.6% (median 9.07) and 90.5% (median 15.62) for S2).
Conversely, only 42.9% and 16.7% of patients had detectable
levels of S1- (median equal to 10) and S2-specific (median equal
to 10) IgM, respectively. Compared with the early week PSO,
only 52.4% of patients, mainly with mild symptoms, developed
anti-NP IgA (median 25.63).
Between 2 and 4 months, sustained levels of S1-, S2-, and NP-
specific IgG were detected in the majority of patients (92.9%
(median 31.49), 89.3% (median 15.32), and 85.7% (median
23.51), respectively). Patients sampled between 5 and 9 months
PSO had similar antibody levels, with a slight decrease in anti-S1Frontiers in Immunology | www.frontiersin.org 5IgG (100% (median 26.65) for S1, 100% (median 16.64) for S2,
and 89.5% (median 29.55) for NP). Conversely, specific IgA
levels decreased (median equal to 10 for S1, S2, and for NP).
Of the subjects, 80.9% developed antibodies with neutralizing
activity (Figure 1B), and a broad variation in nAb titers was
observed. Median plasma IC50 titer was 274.14 (97.00, 831.00),
and 19.1% of patients did not reach the 50% neutralization at the
lowest 1:40 dilution.
S1-reactive IgM and IgA significantly and strongly correlated
with plasma neutralization (r = 0.756 and r = 0.774, respectively,
both p < 0.001) within 7 days PSO, and the correlation was
maintained for S1-IgA within 1 month PSO (r = 0.764, p < 0.001)
(Figure 1C), suggesting a role for the early systemic IgA response
in driving neutralization. To corroborate these results, we tested
the neutralizing potential of IgG- and IgA-purified fractions
from five randomly selected moderate and severe patients
sampled within 30 days PSO. We confirmed the correlation
between binding antibodies and neutralization for all IgA-
purified fractions and for three out of five IgG-purified
fractions. Of note, antibody-depleted fractions had neutralizing
activity, probably due to soluble factors produced during
the cytokine storm triggered in COVID-19 patients and
IgM (Figure 1D).
We next wondered whether the baseline SARS-CoV-2-
specific antibodies drive neutralizing activity. To address this
question, Tobit regression models have been estimated on the
122 symptomatic COVID-19 subjects to investigate the role of
undetectable or detectable antibody levels (values below the
cutoff, ≤10; values above the cutoff, >10, respectively) on
neutralization, while accounting for time PSO, age, sex, and
hospitalization. We found that subjects who developed IgA, IgG,
and IgM towards S1 and IgA and IgG towards S2 above the
established cutoff of 10 had higher IC50 values compared with
that with antibodies below the cutoff. Conversely, S2-reactive
IgM did not affect the development of nAbs (p = 0.5382,
Supplementary Table S2).
Hospitalization, SARS-CoV-2 Antibody
Response, and Neutralization Activity
Once more, Tobit regression models have been estimated to
investigate the role of hospitalization in predicting SARS-CoV-2
antibody response while accounting for age, sex, and time PSO
(Supplementary Table S3; Figures 2A, B). We found a
significant and positive effect of hospitalization on anti S1-IgA
(p = 0.0035) and NP-IgA (p = 0.0024), while hospitalization
played a significant and negative effect on anti-S1-IgG (p = 0.0053).
In addition, age significantly affected anti-S1 IgA (p = 0.007), IgM
(p = 0.009), NP-IgG (p = 0.009), and NP-IgA (p = 0.009) levels and
IC50 (p = 0.0028, transformed with base 2 logarithm). Time PSO
had an impact on the development of IgG response towards S1
(p = 0.0036), S2 (p < 0.001), and NP (p = 0.0037) and specific
IgM response towards S1 (p = 0.0385) and NP (p = 0.0163). Gender
was a significant feature for the development of S1-reactive IgM
only (p = 0.0297).
CART has been used to discriminate the risk of
hospitalization. Among patients sampled after 37 days PSO,November 2021 | Volume 12 | Article 772239
Siracusano et al. Antibody Response Patterns in COVID-19the risk was higher for those having S1 IgA levels equal or higher
than 16 AU (65%, Figure 2C), while for those having S1 IgA
levels lower than 16 AU, the risk was equal to 7%. Among
nonhospitalized patients, anti-S1 IgG better correlated with
neutralizing activity (r = 0.686, p = 0.001) than anti-S2 IgG
(r = 0.459, p = 0.001) and anti-S1 IgA (r = 0.322, p = 0.022,
Figure 3A). In these subjects, the magnitude of the antibody
response did not have any impact on the resolution of the
symptoms (Supplementary Figure S1).
S1-reactive antibodies correlated with neutralization in
hospitalized patients, with S1-IgA playing the dominant role as
nAbs (r = 0.658, p < 0.001, Figure 3B). Of note, this is in line on
what was observed in Figure 1, since hospitalized patients were
collected within 30 days PSO, when the S1-specific IgA response
was higher and predictive for neutralization.Frontiers in Immunology | www.frontiersin.org 6S1-Specific IgA Levels Drive the Clinical
Course of COVID-19
We next evaluated whether clinical and immunological
characteristics of patients allow characterizing the COVID-19
course. An additional decision tree was derived to classify
patients with different COVID-19 symptoms (Figure 4).
Among all the input variables, the algorithm selected
both time from disease onset to worst score and S1-IgA as
those variables best discriminating among patients’ groups.
Indeed, severe patients had a time from symptoms onset to
worst score longer than or equal to 3 days and IgA towards S1
equal to or larger than 28 AU. Moderate patients were
characterized by time from symptoms onset to worst
score above 3 days but IgA towards S1 lower than 28 AU.
Following the tree branches, S1-IgA lower than 28 AU allowedA
B C
FIGURE 2 | SARS-CoV-2 antibodies (A) and IC50 (B) in symptomatic nonhospitalized (n = 50) and hospitalized subjects (n = 72). Decision tree for the classification
of the hospital admission in symptomatic subjects (n = 122) (C).November 2021 | Volume 12 | Article 772239
Siracusano et al. Antibody Response Patterns in COVID-19classifying 72% of patients with moderate symptoms.
Conversely, S1-IgA higher than 28 AU allowed classifying 64%
of subjects with severe disease. This parameter was not pivotal
for classifying patients with mild disease. As a matter of fact,
most of them were classified using the rule of a “time from
disease onset to worst score lower than 3 days” (Figure 4).
Therefore, S1-IgA are a good surrogate marker to discriminateFrontiers in Immunology | www.frontiersin.org 7the broad variety of clinical manifestations of COVID-19 early
after the symptoms onset (Figure 5).
Persistence of the Antibody Response to
SARS-CoV-2 Up to 9 Months
We explored the duration of the antibody response against
SARS-CoV-2 in 72 longitudinally symptomatic recoveredA
B
FIGURE 3 | Spearman’s correlations between IC50 and SARS-CoV-2 antibodies in symptomatic (A) nonhospitalized (n = 50) and (B) hospitalized subjects (n = 72).November 2021 | Volume 12 | Article 772239
Siracusano et al. Antibody Response Patterns in COVID-19patients requiring or not hospitalization (Figure 6). As expected,
anti-S1 and S2-IgM declined up to undetectable levels in the
majority of the two groups, even though three out of 24
nonhospitalized subjects maintained sustainable levels of S1-
IgM up to 6 months PSO. A similar tendency was observed for
anti-S1 IgA, except for some hospitalized patients who enhanced
S1-IgA production even after 8 months PSO. Both hospitalized
and nonhospitalized individuals lost S2-IgA, except for four
nonhospitalized subjects who maintained high levels even after
7 months. Anti-NP IgA and IgG dramatically decreased in both
groups but remained detectable even after 7 months PSO.
Overall, SARS-CoV-2 IgM and IgG decreased during the
follow-up period in infected subjects, especially those with high
antibody levels at the first time point. Strikingly, while S1-IgG
dramatically declined, S2-IgG enhanced over the same period of
time (100–226.8 days) in both patient’s groups, pointing out the
importance of the immunoreactivity towards S2.
NAb titers declined but were still detectable in 11 out of 24
patients not requiring hospitalization and having a sampling
time PSO higher than 6 months. Therefore, nAbs mirrored the
kinetic of the antibody response, with the exception of S2-IgG. A
panel of plasma samples with a range of neutralization titres (40–
9,850 IC50) was tested for their ability to neutralize the B.1.1.7
and B.1.351 genetic lineages. Antibodies raised against the virus
circulating during the first wave of the pandemic reduced their
neutralizing activity with fold change of 1.7 and 7.2, respectively
(Figure 7), as previously reported (15).
Based on considerations on sample size, we then focused on
patients with moderate symptoms to investigate whether the
baseline antibody response (positive/negative) might drive theFrontiers in Immunology | www.frontiersin.org 8nAb response in the longitudinal analysis. Twenty-three patients
with at least two measurements at two different time points were
considered. Time points were categorized by taking into account
three conditions: T0 if the time of sampling from symptom onset
was lower than 30 days, T1 if the time comprised between 30 and
60 days, and T2 if the time was larger than 60 days. Linear mixed
effects models (LME) were estimated to model nAb activity over
time. Along with group and time indicator variables, included as
main effects as well in interaction, gender and age were entered in
the model. The LME model revealed that the baseline levels of S1
and S2-IgA, S1-IgG, and S1-IgM played a role in shaping nAb
activity dynamics.
Post-hoc analyses were performed to compare IC50 of patients
with different baseline levels of antibodies at a fixed time point. It
emerged as a significant difference at the first time point only (p =
0.001 for S1-IgA, p = 0.0034 for S2-IgA, p = 0.0017 for S1-IgG,
and p = 0.0185 for S1-IgM, Supplementary Table S4).DISCUSSION
We proposed a new methodological approach for identifying
homogeneous profiles of patients’ antibody responses within a
precision-medicine perspective thus accounting for individual
sources of variability, thus providing the antibody landscape of
patients mirroring the wide spectrum of clinical manifestations
of SARS-CoV-2 infections.
Nearly all patients developed all classes of antibodies within
the 7 days after the symptoms appeared. Consistent with our and
other previous studies (2, 3), a fraction of both asymptomatic andFIGURE 4 | Decision tree for the classification of the WHO score in symptomatic subjects (n = 122).November 2021 | Volume 12 | Article 772239
Siracusano et al. Antibody Response Patterns in COVID-19symptomatic patients were seronegative. In accordance with
previous studies (5–7), both the magnitude of the individual
antibody response and neutralizing activity displayed great
variability across the cohort, regardless of the severity of the
disease. Reynolds et al. did not find any difference in the potency
of nAbs from asymptomatic and mild patients, whereas lower T-
cell response was a distinct feature of asymptomatic subjects
(16). Severe COVID-19 cases associated with higher antibody
production and neutralization titers (17, 18). We confirmed this
evidence for all the antibody classes with the exception of S1 and
S2 specific IgG levels. Indeed, in contrast with Long et al. (19),
S-specific IgG in asymptomatic subjects were comparable to that
of symptomatic patients sampled within the same time. This is
not surprising when considering that subclinical infections have
similar or lower infectivity than symptomatic ones (20) and the
virus may persist for several weeks after infection (21).Frontiers in Immunology | www.frontiersin.org 9The effect of the antiviral antibody response in COVID-19 is a
matter of debate. SARS-CoV-2 infection in rhesus macaques
induced immune responses protecting from reinfection (22) and
the lack of viral-specific IgG response correlated with poor
outcome in severe patients (23). In contrast, we found that S1-
IgG levels had a negative effect on the risk of hospitalization.
Beyond the breadth of the antibody response, the association
between nAbs and survival is controversial. High titers of nAbs
were associated with poor outcome (17, 24, 25), whereas the early
development of nAbs within the first weeks PSO was critical for
patient survival and virus control (26). We found that baseline
antibody levels (except S2-IgM) addressed the neutralizing
response in COVID-19 patients, but we did not identify any
effect on survival (data not shown).
IgA levels dictated the early SARS-CoV-2 antibody response
in our cohort. Virus-specific IgA developed within 30 days inFIGURE 5 | Graphical sketch of CART analyses showing relevant cutoff values of S1-IgA, allowing discrimination of the broad variety of COVID-19 clinical manifestations.November 2021 | Volume 12 | Article 772239
Siracusano et al. Antibody Response Patterns in COVID-19moderate and severe patients, together with S1-specific IgM and
IgG and NP-reactive IgG. One remarkable finding was that both
IgM and IgA targeting S1 strongly correlated with neutralization
within 7 days PSO, with the strongest contribution of IgA
maintained up to 30 days. The neutralizing potential of IgM
and IgA was reported in SARS-CoV-2 infection (27–29).
Although neutralizing S-specific IgG are known, the
neutralizing potency of monomeric IgA was higher than that
of monomeric IgG (30). Conversely, monomeric IgA reducedFrontiers in Immunology | www.frontiersin.org 10their neutralizing potential compared with IgG counterpart in
recovered patients (31). Several factors might contribute to the
poor outcome of COVID-19 in our patients, albeit they
developed nAbs as soon as symptoms appeared. First, at the
beginning of the outbreak, the spectrum of effective therapeutic
interventions was limited. Secondly, the exuberant production of
inflammatory cytokine in severe conditions might contribute to
the over-production of IgA. Antibodies may function as a
double-edged sword acting as a protective mechanism toA
B
FIGURE 6 | Dynamic of SARS-CoV-2 antibodies in nonhospitalized (n = 35) (A) and hospitalized subjects (n = 37) (B).November 2021 | Volume 12 | Article 772239
Siracusano et al. Antibody Response Patterns in COVID-19control the infection or as a harmful process exacerbating the
disease. Indeed, nonneutralizing or low-affinity nAbs might have
detrimental effect through antibody-dependent enhancing, as
shown for other respiratory infections (32–35).
IgA targeting S1 emerged as a good surrogate marker to
discriminate the broad variety of COVID-19 manifestations early
PSO driving the decision for the appropriate management
of patients. Different classes of biomarkers have been identified
(10). To the best of our knowledge, this is the first study
showing that S1-reactive IgA score may improve risk
stratification by using statistical models to examine the impact
of several variables on specific outcomes. This unconventional
data-driven approach allowed identifying novel correlates of
protection, in agreement with the consideration that binding
antibodies are “good as a correlate-if not better,” recently pointed
out by Cohen (36).
The persistence of SARS-CoV-2-specific antibodies is an open
question. Our longitudinal study confirmed that S1-reactive IgG
dramatically dropped but remained detectable in all patients
even after 8 months PSO, as previously reported (37–39). One
remarkable finding was that S2-IgG enhanced over the same
time. Nguyen-Contant et al. demonstrated markedly increased
levels of S2-IgG in unexposed and convalescent individuals
with S2-reactive memory B cells, probably related to pre-
exposure to human coronaviruses (40). We can speculate that
SARS-CoV-2 infection generated IgG memory B cells reactive
to S2 that cross-reacted with the S2 of seasonal human
coronaviruses, due to the higher homology of S2 than S1
across human coronaviruses (41).
Nowadays, the question has arisen whether the antibody
response to SARS-CoV-2 generated during the first wave of the
pandemic is effective against the emerging variant of concern
(VOC). The B.1.1.7 and B.1.351, first detected in December
2020 in the UK (42) and South Africa (43), respectively, quickly
spread worldwide since extensive mutations on the spikeFrontiers in Immunology | www.frontiersin.org 11enhanced viral transmission. Our and other emerging studies
(44, 45) showed that antibodies raised against the D614G
lineage cross-neutralized the two VOCs but at reduced potency,
that was marked for the B.1.351 variant. These evidences
pointed out the urgent need to implement currently available
vaccine formulations to protect against newly emerging
VOC. Overall, this study provided new evidences to open
opportunities for the early management of infected patients as
soon as they are diagnosed and for implementing the current
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